| Literature DB >> 31074378 |
Yance Feng1,2, Sheng Zhang1,2, Liang Li1,2, Lei M Li3,4,5.
Abstract
BACKGROUND: A key problem in systems biology is the determination of the regulatory mechanism corresponding to a phenotype. An empirical approach in this regard is to compare the expression profiles of cells under two conditions or tissues from two phenotypes and to unravel the underlying transcriptional regulation. We have proposed the method BASE to statistically infer the effective regulatory factors that are responsible for the gene expression differentiation with the help from the binding data between factors and genes. Usually the protein-DNA binding data are obtained by ChIP-seq experiments, which could be costly and are condition-specific.Entities:
Keywords: BASE; Binding strength; DHA; EPA; PUFA; Statistical inference; Transcriptional regulation
Mesh:
Substances:
Year: 2019 PMID: 31074378 PMCID: PMC6509875 DOI: 10.1186/s12859-019-2732-6
Source DB: PubMed Journal: BMC Bioinformatics ISSN: 1471-2105 Impact factor: 3.169
Fig. 1The workflow of the modified BASE using cis-trans binding strength defined by motif frequencies
Fig. 2The validation of the expression profiles obtained by the microarray technique. Left: the kernel density of the gene expression differences between the EPA&DHA diet and control, with normalization and without normalization respectively. After normalization, both the bias, as measure by the closeness of the mode to zero, and the variation was reduced significantly. Right: the scatter plot of the expression fold changes of some significantly differentially expressed genes obtained by microarray and qRT-PCR, respectively. Their Pearson correlation coefficient is 0.73
Fig. 3The effects of EPA&DHA diet in the mouse small intestine cells and corresponding TFs/motifs
Partial inference results of the significant TFs/motifs in the exploration of EPA&DHA dietary effects
| TFs | Motifs | P-values, upside** | P-values, downside** | Regulation* | Functions |
|---|---|---|---|---|---|
| PPARα | V$PPARA_01 | 0.00010 | 0.55 | ↑ | Attenuate hyperlipidemia [ |
| V$PPARDR1_Q2 | 0.00030 | 0.37 | |||
| PPARγ | V$PPARG_01 | < 0.00010 | 0.22 | ↑ | |
| V$PPARG_02 | 0.00010 | 0.17 | |||
| C/EBPs | V$CEBP_C | 0.0049 | 0.69 | ↑ | Induce adipogenesis [ |
| V$CEBPA_Q6 | 0.0058 | 0.57 | |||
| V$CEBPB_02 | 0.0039 | 0.66 | |||
| V$CEBPD_Q6_01 | 0.0043 | 0.74 | |||
| V$CEBPE_01 | 0.0006 | 0.97 | |||
| V$CEBPG_Q6 | 0.0019 | 0.47 | |||
| NF-κB | V$NFKB_C | 0.73 | 0.0039 | ↓ | Reduce inflammation [ |
| V$NFKB_Q6 | 0.33 | 0.0033 | |||
| Stats | V$STAT1_Q6 | 0.011 | 0.27 | ↑ | |
| V$STAT4_Q5 | < 0.00010 | 0.26 | |||
| V$STAT5A_02 | 0.0074 | 0.30 | |||
| Ets family | V$ETS2_Q6 | 0.91 | 0.011 | ↓ | Inhibit angiogenesis [ |
| V$PEA3_01 | 0.33 | 0.0050 | |||
| V$CETS1_01 | 0.40 | 0.0066 | |||
| V$CETS2_02 | 0.46 | 0.036 | |||
| V$ELF_02 | 0.17 | 0.0098 | |||
| V$ELF4_02 | 0.17 | 0.0047 | |||
| V$ELF5_03 | 0.76 | 0.011 | |||
| V$ERF_01 | 0.43 | 0.0269 | |||
| V$ERF_02 | 0.14 | 0.0084 | |||
| V$ETV3_01 | 0.17 | 0.0083 | |||
| Rora | V$RORA_Q4 | 0.0035 | 0.34 | ↑ | Enhance circadian rhythm [ |
| V$RORA2_01 | 0.00020 | 0.89 | |||
| Dbp | V$DBP_Q6_01 | 0.015 | 0.98 | ↑ | |
| SP1 | V$SP1_01 | 0.37 | 0.0099 | ↓ | – |
| Ahr | V$AHR_01 | 0.058 | 0.0082 | ↓ | – |
| Arnt | V$ARNT_01 | 0.23 | 0.013 | ↓ | Reduce hypoxia [ |
* ↑↓: The TF/motif was up/down-regulated in modified BASE.
** Tests with the up/down-regualted genes, 10,000 permutations.
Partial conclusions from the inference of TFs regulation were verified by gene functional enrichment analysis
| Conclusions | Pathways | P-values, upside* | P-values, downside* | Regulation |
|---|---|---|---|---|
| Enhance insulin sensitivity | PPAR signaling pathway (KEGG) | 3.98e-8 | ≈1 | ↑ |
| Peroxisome (KEGG) | 4.62e-11 | ≈1 | ||
| peroxisome organization | 2.99e-4 | ≈1 | ||
| Promote fatty acid metabolism | fatty acid metabolism (KEGG) | 1.86e-9 | ≈1 | ↑ |
| cellular lipid metabolic process (GO) | 3.49e-7 | ≈1 | ||
| long-chain fatty acid metabolic process (GO) | 9.54e-6 | ≈1 | ||
| very long-chain fatty acid metabolic process (GO) | 6.73e-5 | ≈1 | ||
| regulation of fatty acid oxidation (GO) | 5.30e-4 | ≈1 | ||
| fatty acid beta-oxidation (GO) | 1.17e-5 | ≈1 | ||
| Inhibit angiogenesis | blood vessel development (GO) | 0.996 | 3.72e-3 | ↓ |
| Reduce inflammation | intestinal immune network for IgA production (KEGG) | 0.995 | 5.32e-3 | ↓ |
* Gene functional enrichemnt in the up/down-side with Wilcox rank sum test, see Method.